<DOC>
	<DOC>NCT00957073</DOC>
	<brief_summary>The purpose of the HOPE4HF trial is to demonstrate the safety and efficacy of the Rheos Baroreflex Activation Therapy System in subjects with heart failure with an EF ≥ 40% in a prospective, randomized trial.</brief_summary>
	<brief_title>Rheos HOPE4HF (Health Outcomes Prospective Evaluation for Heart Failure With Ejection Fraction (EF) ≥ 40%) Trial</brief_title>
	<detailed_description>This study closed to enrollment before adequate endpoint data was collected and before enrollment was completed. The study was not stopped for safety or futility, but for business/strategic reasons due to production of a new generation of the device. Currently, subjects are still enrolled in the trial under long-term follow-up.</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>At least 21 years of age Have bilateral carotid bifurcations that are below the level of the mandible Have a left ventricular ejection fraction ≥ 40% Symptomatic heart failure with elevated blood pressure Elevated brain natriuretic peptide (BNP) or nterminal probrain natriuretic peptide (NTproBNP) Serum creatine ≤ 2.5 mg/dL and not being treated with dialysis Known or suspected baroreflex failure or autonomic neuropathy History of symptomatic bradyarrhythmias, pericardial constriction, infiltrative cardiomyopathy, or primary hypertrophic cardiomyopathy Solid organ or hematologic transplant History of prior surgery, radiation, or stent placement in carotid sinus region Life expectancy of less than one year for noncardiovascular reasons</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Diastolic dysfunction</keyword>
</DOC>